WARNING LETTER

Date: December 21, 2020

TO: customerservice@doctorschoice.org – Chris LaVoie, Riverstone Institute LLC
51668 Blue River Dr
Blue River, OR 97413-9401

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https://www.doctorschoice.org on September 22, 2020, and December 2, 2020, respectively. The FDA has observed that your website offers the products “Flu Immune Drops,” “L-Lysine,” “Lysine Extra,” and “Monolaurin” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).

There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19

---

1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).
include:

- On the webpage titled “Corona Virus”:
  “Products that may Slow Viruses and Boost the Immune System . . .
  The products below are worth considering in supporting your immune system and helping your
  body fight off Viruses.” [from your website https://www.doctorschoice.org/Corona-
  Virus_c_381.html, where you then list and link to various recommended products sold on your
  website, including those cited below]

- “L-Lysine . . . Helps boost immune system response to fight viruses and bacteria that lead to
  illness. . . . L-Lysine 500 mg by Ecological Formulas features Lysine as its key ingredient, an
  essential amino acid that helps the body in fighting viruses . . . .” [from your website
  https://www.doctorschoice.org/L-Lysine-500mg-Ecological-Formulas.html]

- “Lysine Extra by Vitanica
Immune Support – Anti Viral
Utilizing clinical data, botanical research and nutritional research studies, this formula has been
developed for its anti-viral immune modulating . . . properties . . . .” [from your website
https://www.doctorschoice.org/Lysine-Extra-Vitanica.html]

- “Monolaurin by Ecological Formulas
Immune Support
Studies have shown that Lauric Acid helps the body fight minor viral infections . . . . Taking these
capsules . . . for infections can help you recover faster and protect you from getting sick again.
This product contains 600 mg of monolaurin to help treat and prevent viral and bacterial infections
. . . .” [from your website https://www.doctorschoice.org/Monolaurin-600-mg-Ecological-
Formulas.html]

You should take immediate action to correct the violations cited in this letter. This letter is not meant to
be an all-inclusive list of violations that exist in connection with your products or operations. It is your
responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA’s
implementing regulations. We advise you to review your websites, product labels, and other labeling and
promotional materials to ensure that you are not misleadingly representing your products as safe and
effective for a COVID-19-related use for which they have not been approved by FDA and that you do not
make claims that misbrand the products in violation of the FD&C Act. **Within 48 hours, please send an**
**email to COVID-19-Task-Force-CFSAN@fda.hhs.gov** **describing the specific steps you have taken to**
correct these violations. Include an explanation of each step being taken to prevent the recurrence of
violations, as well as copies of related documentation. Failure to immediately correct the violations cited
in this letter may result in legal action, including, without limitation, seizure and injunction.

FDA is advising consumers not to purchase or use certain products that have not been approved,
cleared, or authorized by FDA and that are being misleadingly represented as safe and/or effective for
the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of
firms and websites that have received warning letters from FDA concerning the sale or distribution of
COVID-19 related products in violation of the FD&C Act. This list can be found at
Once you have taken corrective actions to cease the sale of your unapproved and unauthorized products
for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been
confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate
corrective action.

If you cannot complete corrective action within 48 hours, state the reason for the delay and the time
within which you will complete the corrections. If you believe that your products are not in violation of the
FD&C Act, include your reasoning and any supporting information for our consideration.

If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.

Please direct any inquiries to FDA at COVID-19-Task-Force-CFSAN@fda.hhs.gov.

In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.

Sincerely,

William A. Correll Jr
Director
Office of Compliance
Center for Food Safety and Applied Nutrition
Food and Drug Administration

Sincerely,

SERENA VISWANATHAN
Acting Associate Director
Division of Advertising Practices
Federal Trade Commission